Post by Norgine

Now that EASL 2026 has come to a close, we want to say a big thank you to EASL and the wider hepatology community for a highly engaging congress with a diverse programme exploring the evolving landscape of liver disease research and care. The conversations last week reinforced the importance of collaboration, across research, clinical practice and partners, to address unmet needs in liver disease and reach more patients across Europe. With hepatology at the core of who we are, and a long‑standing heritage in this space, we’ll continue to strengthen our focus and partnerships, including our recently announced collaboration with Vir Biotechnology. Sharing her reflections from EASL, Our CEO, @Janneke van der Kamp highlights why this moment matters and what comes next. #EASL2026 #Collaboration #PatientsFirst

Video Content